Weston, MA-based Biogen Idec (NASDAQ: [[ticker:BIIB]]) said today that it has received a positive opinion from a committee of the European Medicines Agency, which should pave the way to begin sales in Europe of fampridine (Fampyra) as a new treatment for multiple sclerosis. Based on the committee recommendation, Biogen Idec said it expects to be cleared to begin sales within 67 days. Hawthorne, NY-based Acorda Therapeutics (NASDAQ: [[ticker:ACOR]]) developed the drug, sells it in the U.S., and granted Biogen a license to commercialize the product outside the U.S.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
